These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

606 related items for PubMed ID: 18438840

  • 1. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab.
    Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A, To K, Harashima S, Hatta N, Harada M.
    Arthritis Rheum; 2008 May; 58(5):1248-57. PubMed ID: 18438840
    [Abstract] [Full Text] [Related]

  • 2. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor.
    Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian DK, Salfeld J, Sasso EH.
    Clin Immunol; 2009 May; 131(2):308-16. PubMed ID: 19188093
    [Abstract] [Full Text] [Related]

  • 3. Anti-tumor necrosis factor-α antibodies induce regulatory macrophages in an Fc region-dependent manner.
    Vos AC, Wildenberg ME, Duijvestein M, Verhaar AP, van den Brink GR, Hommes DW.
    Gastroenterology; 2011 Jan; 140(1):221-30. PubMed ID: 20955706
    [Abstract] [Full Text] [Related]

  • 4. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.
    Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, Brown D, Robinson M, Bourne T.
    Inflamm Bowel Dis; 2007 Nov; 13(11):1323-32. PubMed ID: 17636564
    [Abstract] [Full Text] [Related]

  • 5. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
    Bombardieri S, Ferraccioli G, Ferri C, Galeazzi M, Lapadula G, Cerinic MM, Montecucco C, Triolo G, Trotta F, Valentini G.
    Reumatismo; 2009 Nov; 61 Suppl 1():1-23. PubMed ID: 19999184
    [Abstract] [Full Text] [Related]

  • 6. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action.
    Bourne T, Fossati G, Nesbitt A.
    BioDrugs; 2008 Nov; 22(5):331-7. PubMed ID: 18778114
    [Abstract] [Full Text] [Related]

  • 7. Tumor necrosis factor inhibitors block apoptosis of human epithelial cells of the salivary glands.
    Sisto M, D'Amore M, Caprio S, Mitolo V, Scagliusi P, Lisi S.
    Ann N Y Acad Sci; 2009 Aug; 1171():407-14. PubMed ID: 19723083
    [Abstract] [Full Text] [Related]

  • 8. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages.
    Atreya R, Zimmer M, Bartsch B, Waldner MJ, Atreya I, Neumann H, Hildner K, Hoffman A, Kiesslich R, Rink AD, Rau TT, Rose-John S, Kessler H, Schmidt J, Neurath MF.
    Gastroenterology; 2011 Dec; 141(6):2026-38. PubMed ID: 21875498
    [Abstract] [Full Text] [Related]

  • 9. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept.
    Shen C, Assche GV, Colpaert S, Maerten P, Geboes K, Rutgeerts P, Ceuppens JL.
    Aliment Pharmacol Ther; 2005 Feb 01; 21(3):251-8. PubMed ID: 15691299
    [Abstract] [Full Text] [Related]

  • 10. Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior?
    Rigby WF.
    Nat Clin Pract Rheumatol; 2007 Apr 01; 3(4):227-33. PubMed ID: 17396108
    [Abstract] [Full Text] [Related]

  • 11. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, Baumgartner SW.
    J Rheumatol; 2011 Jul 01; 38(7):1273-81. PubMed ID: 21572150
    [Abstract] [Full Text] [Related]

  • 12. Differential effects of anti-TNF-alpha drugs on fibroblast-like synoviocyte apoptosis.
    Pattacini L, Boiardi L, Casali B, Salvarani C.
    Rheumatology (Oxford); 2010 Mar 01; 49(3):480-9. PubMed ID: 20040530
    [Abstract] [Full Text] [Related]

  • 13. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA, Klingman D, Hazard E, Ray S.
    Clin Ther; 2009 Apr 01; 31(4):825-35. PubMed ID: 19446156
    [Abstract] [Full Text] [Related]

  • 14. Differentiating the efficacy of tumor necrosis factor inhibitors.
    Haraoui B.
    J Rheumatol Suppl; 2005 Mar 01; 74():3-7. PubMed ID: 15742457
    [Abstract] [Full Text] [Related]

  • 15. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha.
    Mitoma H, Horiuchi T, Hatta N, Tsukamoto H, Harashima S, Kikuchi Y, Otsuka J, Okamura S, Fujita S, Harada M.
    Gastroenterology; 2005 Feb 01; 128(2):376-92. PubMed ID: 15685549
    [Abstract] [Full Text] [Related]

  • 16. Differences in binding and effector functions between classes of TNF antagonists.
    Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, Louie JS, Kohno T.
    Cytokine; 2009 Feb 01; 45(2):124-31. PubMed ID: 19128982
    [Abstract] [Full Text] [Related]

  • 17. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.
    Bonafede MM, Gandra SR, Fox KM, Wilson KL.
    J Med Econ; 2012 Feb 01; 15(4):635-43. PubMed ID: 22332705
    [Abstract] [Full Text] [Related]

  • 18. The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α.
    Ueda N, Tsukamoto H, Mitoma H, Ayano M, Tanaka A, Ohta S, Inoue Y, Arinobu Y, Niiro H, Akashi K, Horiuchi T.
    Inflamm Bowel Dis; 2013 May 01; 19(6):1224-31. PubMed ID: 23619715
    [Abstract] [Full Text] [Related]

  • 19. Outside-to-inside signaling through transmembrane tumor necrosis factor reverses pathologic interleukin-1beta production and deficient apoptosis of rheumatoid arthritis monocytes.
    Meusch U, Rossol M, Baerwald C, Hauschildt S, Wagner U.
    Arthritis Rheum; 2009 Sep 01; 60(9):2612-21. PubMed ID: 19714631
    [Abstract] [Full Text] [Related]

  • 20. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
    Gao X, Wendling D, Botteman MF, Carter JA, Rao S, Cifaldi M.
    J Med Econ; 2012 Sep 01; 15(6):1054-63. PubMed ID: 22563743
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.